,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-06-25 05:20:00,Medical devices major St. Jude Medical ( STJ ) has won the European CE Mark approval for its MultiPoint Pacing Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D).,0.9474624395370483,0.020351136103272438,0.03218637406826019,positive,0.9271113276481628
1,2013-06-25 05:20:00,"This one-of-a-kind quadripolar device from the company's Cardiac Rhythm Management (CRM) business, featuring the Quartet lead, improves hemodynamic support in patients receiving cardiac resynchronization therapy (CRT).",0.8562900424003601,0.014077655971050262,0.12963233888149261,positive,0.8422123789787292
2,2013-06-25 05:20:00,"Assura's product line is primarily meant for patients prone to sudden cardiac death (SCD) due to abnormally fast and potentially fatal cardiac rhythms, as well as for patients at risk of heart failure.",0.035747501999139786,0.006008191499859095,0.9582443237304688,neutral,0.02973931096494198
3,2013-06-25 05:20:00,The Assura implantable cardioverter defibrillators (ICDs) and CRT-Ds address this problem and offer precise solutions.,0.21318067610263824,0.009069621562957764,0.7777497172355652,neutral,0.20411105453968048
4,2013-06-25 05:20:00,The new Quadra Assura MP CRT-D has the advantage of MultiPoint Pacing (MPP) technology that delivers pacing to multiple locations in the heart rather than the traditional single pulse for each heartbeat.,0.27966779470443726,0.010751493275165558,0.7095807194709778,neutral,0.2689163088798523
5,2013-06-25 05:20:00,"Moreover, it is built on the industry's first Quadripolar Pacing System.",0.4209359884262085,0.009324414655566216,0.5697395205497742,neutral,0.4116115868091583
6,2013-06-25 05:20:00,The four electrodes of the Quartet lead provides enhanced flexibility for different pacing configurations.,0.5758053660392761,0.009948758408427238,0.4142458438873291,positive,0.5658566355705261
7,2013-06-25 05:20:00,"Earlier in Nov 2012, St. Jude had received the CE Mark approval for its Assura family of ICDs and CRT-Ds (including Quadra Assura CRT-D, Unify Assura CRT-D and Fortify Assura ICD), featuring the Shockguard technology.",0.8338866829872131,0.01024121418595314,0.15587209165096283,positive,0.8236454725265503
8,2013-06-25 05:20:00,The Assura product line gained the approval of the U.S. Food and Drug Administration (FDA) in May 2012.,0.6916144490242004,0.010222401469945908,0.29816320538520813,positive,0.6813920736312866
9,2013-06-25 05:20:00,"At present, about 14 million Europeans ail from heart failure.",0.03355276212096214,0.70880126953125,0.25764602422714233,negative,-0.6752485036849976
10,2013-06-25 05:20:00,St. Jude Medical recently launched the world's first quadripolar MultiPoint Pacing technology in Europe.,0.788103461265564,0.011738928034901619,0.20015759766101837,positive,0.7763645052909851
11,2013-06-25 05:20:00,Quadripolar Pacing is becoming the new standard of care in CRT.,0.36967551708221436,0.0104200579226017,0.6199043989181519,neutral,0.35925546288490295
12,2013-06-25 05:20:00,This provides a competitive advantage to the company's CRT segment to gain market share in the ICD market.,0.9395739436149597,0.015275651589035988,0.045150402933359146,positive,0.9242982864379883
13,2013-06-25 05:20:00,Several studies have demonstrated that CRT pacing delivered by an ICD can improve patient outcome.,0.8408073782920837,0.015295695513486862,0.1438969224691391,positive,0.8255116939544678
14,2013-06-25 05:20:00,A study presented at the Heart Rhythm Society (HRS) 2013 meeting revealed that 89% patients treated with STJ's MPP responded positively after 3 months.,0.8703165650367737,0.028411488980054855,0.10127197951078415,positive,0.8419050574302673
15,2013-06-25 05:20:00,This represents a 20% hike from about 70% response rate from traditional CRT therapy.,0.9362242817878723,0.023393722251057625,0.04038193076848984,positive,0.9128305315971375
16,2013-06-25 05:20:00,"Additionally, St. Jude is conducting a MultiPoint Pacing clinical study in the U.S. under an Investigational Device Exemption (IDE).",0.15739081799983978,0.006812131032347679,0.835797131061554,neutral,0.15057869255542755
17,2013-06-25 05:20:00,Patients have been implanted with the Quadra Assura MP CRT-D and Quartet lead.,0.08198018372058868,0.017360622063279152,0.9006591439247131,neutral,0.06461956351995468
18,2013-06-25 05:20:00,Another single-center study will evaluate the efficiency of CRT with MPP at various programmed parameters for 6 months.,0.11521203815937042,0.005803219508379698,0.878984808921814,neutral,0.10940881818532944
19,2013-06-25 05:20:00,"Moreover, a post-market study is expected to be initiated by the company in Europe to further assess the performance of MPP therapy in patients unresponsive to standard CRT.",0.4359518587589264,0.010050226002931595,0.5539979338645935,neutral,0.4259016215801239
20,2013-06-25 05:20:00,"However, St. Jude's core CRM division is still underperforming.",0.030361400917172432,0.9501043558120728,0.019534289836883545,negative,-0.9197429418563843
21,2013-06-25 05:20:00,Revenues from the CRM division fell 8% year over year in the first quarter of 2013.,0.01768123358488083,0.9733211398124695,0.008997714146971703,negative,-0.9556398987770081
22,2013-06-25 05:20:00,"The beleaguered ICD market, as reflected by sustained implant volume pressure and the Riata/Durata lead issue, continues to hurt CRM results.",0.02041614055633545,0.9668582081794739,0.012725592590868473,negative,-0.9464420676231384
23,2013-06-25 05:20:00,ICD sales declined 5% in the first quarter but we believe that market trends will stabilize soon.,0.042124126106500626,0.9188238382339478,0.039051953703165054,negative,-0.876699686050415
24,2013-06-25 05:20:00,"St. Jude's peer Boston Scientific ( BSX ) also reported disappointing CRM sales in the first quarter of 2013, indicating sustained softness in the CRM market.",0.019286779686808586,0.9697902202606201,0.010922987014055252,negative,-0.9505034685134888
25,2013-06-25 05:20:00,"However, surprisingly, after a series of lackluster quarterly results, Medtronic ( MDT ) reported encouraging CRM and ICD sales in its last reported quarter.",0.9423432946205139,0.036125361919403076,0.021531328558921814,positive,0.9062179327011108
26,2013-06-25 05:20:00,St. Jude currently has a Zacks Rank #3 (Hold).,0.043040964752435684,0.02330453135073185,0.9336544275283813,neutral,0.019736433401703835
27,2013-06-25 05:20:00,"While we remain on the sidelines regarding STJ, Haemonetics ( HAE ), with a Zacks Rank #1 (Strong Buy), warrants a look.",0.7590876817703247,0.01831112615764141,0.22260120511054993,positive,0.740776538848877
28,2013-06-25 05:20:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
29,2013-06-25 05:20:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
